[Treatment of Paget's disease with synthetic human calcitonin (author's transl)].
7 patients with Paget's disease were treated with synthetic human calcitonin over 6 months. 6 patients responded favourably to treatment and showed a marked decrease in serum alkaline phosphatase and urinary hydroxyproline. Subjectively, these patients reported a considerable decrease in pain. 1 patient did not respond to treatment. No side effects requiring premature termination of therapy were recorded. No regression of the radiological findings was achieved, but 3 patients showed a distinct improvement of the scintigrams. The indications for therapy are discussed.
D000469:Alkaline Phosphatase / Q000378:metabolism; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007279:Injections, Subcutaneous; D008297:Male; D010001:Osteitis Deformans / Q000188:drug therapy*; D010710:Phosphates / Q000097:blood; D011859:Radiography; D011877:Radionuclide Imaging
D010710:Phosphates; D002116:Calcitonin; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium
Die Behandlung des Morbus Paget mit synthetischem, humanem Calcitonin.